comprehensive gene profiling

Canary Oncoceutics is a cancer diagnostics company developing genomic profiling tests for early detection and personalized treatment guidance. Its tests are CLIA-certified and CAP-Accredited for solid and liquid tumors, analyzing genes to identify mutations for targeted therapy, immunotherapy, and cancer risk assessment. The company also pursues research collaborations and companion diagnostic development.

Read more

AI-powered insightsclinical trialscompanion diagnostic developmentgenomic profilingliquid biopsy / ctDNA analysis